XSHE
002390
Market cap853mUSD
Oct 09, Last price
3.01CNY
1D
2.38%
1Q
8.27%
Jan 2017
-69.57%
IPO
-36.50%
Name
Guizhou Xinbang Pharmaceutical Co Ltd
Chart & performance
P/E
48.64
P/S
1.04
EPS
0.06
Div yield, %
2.04%
Shrs. gr., 5y
3.67%
Rev. gr., 5y
-0.83%
Revenues
5.61b
-7.04%
Net income
120m
+18.65%
CFO
752m
+18.49%
Dividend
Sep 29, 20260.03 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guizhou Xinbang Pharmaceutical Co., Ltd. specializes in the entire process of researching, developing, manufacturing, and distributing both traditional Chinese herbal medicines and cutting-edge biological pharmaceuticals. The company's operations span across China and international markets. Its diverse range of pharmaceutical offerings covers treatments for cardiovascular and cerebrovascular conditions, digestive system disorders, endocrine imbalances, tumor and immune regulation, blood system ailments, rheumatism and rheumatoid diseases, and urinary tract issues. Additionally, it provides antipyretic analgesics, cold medications, gynecological therapies, and anti-infective drugs. Founded in 1995, the firm's headquarters are situated in Guiyang, China.
Key people
Yafang Lu
Deputy General Manager · since 2015
Chi Luo
Deputy General Manager · since 2022
Yayun Xiao
Chief Financial Officer, Deputy General Manager · since 2015
Jieqing Zhang
Deputy General Manager · since 2020
Chuan Chen
Deputy General Manager, Secretary of the Board · since 2014
Ji An
Chairman of the Board · since 2022
Yi Ding
Director · since 2024
Lingzhong Kong
General Manager, Director · since 2016
Xiangqian Lu
Chief Investment Officer, Director · since 2024
Qianxian Ma
Director · since 2024
Yifeng Liu
Independent Director · since 2024
Jie Liu
Independent Director · since 2024
Gang Qiu
Independent Director · since 2021
Headquarters & legal address
依族苗族自治州贵州省黔南布依族苗族自治州罗甸县龙坪镇信邦大道48号
黔南布依族苗族自治州, GZ 100000
CN
黔南布依族苗族自治州, GZ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||